U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H34Cl2N6O3S2
Molecular Weight 649.655
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVATROMBOPAG

SMILES

OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6

InChI

InChIKey=OFZJKCQENFPZBH-UHFFFAOYSA-N
InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)

HIDE SMILES / InChI
Molecular Formula C29H34Cl2N6O3S2
Molecular Weight 649.655
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Avatrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production. Avatrombopag was discovered by Yamanouchi Pharmaceutical, developed by AkaRx which late became acquired by Dova Pharmaceuticals. In 2018 avatrombopag was approved by the FDA for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.

Originator

Yamanouchi Pharmaceutical
31
Curator's Comment: In April 2005, Astellas Pharmaceuticals was formed from the merger of Yamanouchi Pharmaceutical and Fujisawa Healthcare. In November 2005, AkaRx was formed as a spin out of Yamanouchi Pharma America (YPA), now part of Astellas Pharmaceuticals. Worldwide rights for AKR-501 have been licensed to AkaRx. In 2010 AkaRx became a wholly owned subsidiary of Eisai Inc, and in 2016 rights to the drug were acquired by Dova Pharmaceuticals.

Approval Year

2018
436
Targets

Targets

Primary TargetPharmacologyConditionPotency
Thrombopoietin receptor
8
Target ID: P40238
Gene ID: 4352.0
Gene Symbol: MPL
Target Organism: Homo sapiens (Human)
Agonist
2678
 3.3 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
DOPTELET

Approved Use

Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Launch Date

2018
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
284 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
388 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30203841
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
95.4 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
117 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
183 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
164 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10000 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
10863.5 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30203841
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3160 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3340 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4840 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5900 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
18 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30203841
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18.6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
18 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28339166/
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AVATROMBOPAG plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
healthy, 25.5 years
n = 6
Health Status: healthy
Age Group: 25.5 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
Other AEs: Dysgeusia, Flatulence...
Other AEs:
Dysgeusia (16.7%)
Flatulence (16.7%)
Dizziness (16.7%)
Headache (16.7%)
Diarrhoea (16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Other AEs: Pyrexia, Abdominal pain...
Other AEs:
Pyrexia (8%)
Abdominal pain (7%)
Nausea (7%)
Headache (7%)
Fatigue (3%)
Edema peripheral (4%)
Hyponatremia (serious, 8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Disc. AE: Anemia, Pyrexia...
Other AEs: Pyrexia, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Anemia (0.4%)
Pyrexia (0.4%)
Myalgia (0.4%)
Other AEs:
Pyrexia (11%)
Abdominal pain (6%)
Nausea (6%)
Headache (4%)
Fatigue (4%)
Edema peripheral (3%)
Hyponatremia (serious, 7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Other AEs: Gastrointestinal disorders, General disorders and administration site conditions...
Other AEs:
Gastrointestinal disorders (25.2%)
General disorders and administration site conditions (14.8%)
Nervous system disorders (7.8%)
Injury, poisoning and procedural complications (2.6%)
Infection (9.6%)
Infestation (9.6%)
Respiratory disorder (8.7%)
Thoracic disorders (excl lung and pleura) (8.7%)
Mediastinal disorders (8.7%)
Musculoskeletal disorder (5.2%)
Connective tissue disorders (5.2%)
Metabolism disorders NEC (5.2%)
General nutrition disorder (5.2%)
Skin disorder (1.7%)
Skin and subcutaneous tissue disorders (1.7%)
Blood disorder (3.5%)
Lymphatic system disorders NEC (3.5%)
Psychiatric disorders (4.3%)
Urinary tract disorder NOS (3.5%)
Renal disorder (3.5%)
Vascular disorders (0.9%)
Hepatobiliary disorders (1.7%)
Eye disorders (0.9%)
Cardiac disorders (0.9%)
Disorder ear (0.9%)
Labyrinthine disorders (0.9%)
Endocrine disorders (0.9%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Other AEs: Gastrointestinal disorders, General disorders and administration site conditions...
Other AEs:
Gastrointestinal disorders (29.6%)
General disorders and administration site conditions (23.9%)
Nervous system disorders (8.8%)
Injury, poisoning and procedural complications (10.1%)
Infection (3.1%)
Infestation (3.1%)
Respiratory disorder (4.4%)
Thoracic disorders (excl lung and pleura) (4.4%)
Mediastinal disorders (4.4%)
Musculoskeletal disorder (6.9%)
Connective tissue disorders (6.9%)
Metabolism disorders NEC (3.8%)
General nutrition disorder (3.8%)
Skin disorder (5%)
Skin and subcutaneous tissue disorders (5%)
Blood disorder (3.8%)
Lymphatic system disorders NEC (3.8%)
Psychiatric disorders (3.1%)
Urinary tract disorder NOS (1.3%)
Renal disorder (1.3%)
Vascular disorders (2.5%)
Hepatobiliary disorders (1.9%)
Eye disorders (2.5%)
Cardiac disorders (0.6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
AEs

AEs

AESignificanceDosePopulation
Diarrhoea 16.7%
100 mg single, oral
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
healthy, 25.5 years
n = 6
Health Status: healthy
Age Group: 25.5 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
Dizziness 16.7%
100 mg single, oral
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
healthy, 25.5 years
n = 6
Health Status: healthy
Age Group: 25.5 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
Dysgeusia 16.7%
100 mg single, oral
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
healthy, 25.5 years
n = 6
Health Status: healthy
Age Group: 25.5 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
Flatulence 16.7%
100 mg single, oral
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
healthy, 25.5 years
n = 6
Health Status: healthy
Age Group: 25.5 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
Headache 16.7%
100 mg single, oral
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
healthy, 25.5 years
n = 6
Health Status: healthy
Age Group: 25.5 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/30203841
Fatigue 3%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Edema peripheral 4%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Abdominal pain 7%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Headache 7%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Nausea 7%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Pyrexia 8%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Hyponatremia serious, 8%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Anemia 0.4%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Myalgia 0.4%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Pyrexia 0.4%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Pyrexia 11%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Edema peripheral 3%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Fatigue 4%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Headache 4%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Abdominal pain 6%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Nausea 6%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Hyponatremia serious, 7%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
Cardiac disorders 0.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Disorder ear 0.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Endocrine disorders 0.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Eye disorders 0.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Labyrinthine disorders 0.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Vascular disorders 0.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Hepatobiliary disorders 1.7%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Skin and subcutaneous tissue disorders 1.7%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Skin disorder 1.7%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
General disorders and administration site conditions 14.8%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Injury, poisoning and procedural complications 2.6%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Gastrointestinal disorders 25.2%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Blood disorder 3.5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Lymphatic system disorders NEC 3.5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Renal disorder 3.5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Urinary tract disorder NOS 3.5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Psychiatric disorders 4.3%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Connective tissue disorders 5.2%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
General nutrition disorder 5.2%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Metabolism disorders NEC 5.2%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Musculoskeletal disorder 5.2%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Nervous system disorders 7.8%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Mediastinal disorders 8.7%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Respiratory disorder 8.7%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Thoracic disorders (excl lung and pleura) 8.7%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Infection 9.6%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Infestation 9.6%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 115
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Cardiac disorders 0.6%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Renal disorder 1.3%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Urinary tract disorder NOS 1.3%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Hepatobiliary disorders 1.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Injury, poisoning and procedural complications 10.1%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Eye disorders 2.5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Vascular disorders 2.5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
General disorders and administration site conditions 23.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Gastrointestinal disorders 29.6%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Infection 3.1%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Infestation 3.1%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Psychiatric disorders 3.1%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Blood disorder 3.8%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
General nutrition disorder 3.8%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Lymphatic system disorders NEC 3.8%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Metabolism disorders NEC 3.8%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Mediastinal disorders 4.4%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Respiratory disorder 4.4%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Thoracic disorders (excl lung and pleura) 4.4%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Skin and subcutaneous tissue disorders 5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Skin disorder 5%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Connective tissue disorders 6.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Musculoskeletal disorder 6.9%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Nervous system disorders 8.8%
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
unhealthy, 58 years (range: 19-86 years)
n = 159
Health Status: unhealthy
Condition: thrombocytopenia
Age Group: 58 years (range: 19-86 years)
Sex: M+F
Population Size: 159
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1037

inhibitor
1767

inducer
389
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
BCRP
699

OAT3
642

CYP1A
72

CYP2B6
810

CYP2C8
911

CYP2C19
1478

CYP2E1
882

CYP3A
214

OAT1
599

OCT2
647

OATP1B1
788

OATP1B3
706
CYP3A
191

P-gp
1537

BCRP
561

OATP1B1
406

OATP1B3
350

OAT1
326

OAT3
339

OCT2
355

MATE1
135

MATE2
96
CYP2C8
168

CYP1A2
701

CYP2B6
547

CYP3A
129
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A
121
 no
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A
298
 no
CYP3A
298
 no
OAT1
603
 no
OATP1B1
803
 no
OATP1B3
715
 no
OCT2
648
 no
CYP2C8
965
 weak
CYP2C9
1819
 weak
BCRP
773
 yes
OAT3
644
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1037
 major
CYP3A
191
 major
BCRP
561
 no
MATE1
135
 no
MATE2
96
 no
OAT1
326
 no
OAT3
339
 no
OATP1B1
406
 no
OATP1B3
350
 no
OCT2
355
 no
P-gp
1537
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY561084
https://www.001chemical.com/chem/570406-98-3
AA Blocks
AA00ECCF
https://www.aablocks.com/goods/Goods/detail?id=AA00ECCF
Achemtek
0102-012478
http://www.achemtek.com/570406-98-3
Adooq BioScience
A14087
https://www.adooq.com/avatrombopag.html
Alfa Chemistry
570406-98-3
https://www.alfa-chemistry.com/akr-501-cas-570406-98-3-item-292701.htm
Angene
AGN-PC-0SMVXA
http://www.angenechemical.com/productshow/AGN-PC-0SMVXA.html
BioChemPartner
BCP28031
http://www.biochempartner.com/570406-98-3-BCP28031
Chem Scene
CS-3397
http://www.chemscene.com/570406-98-3.html
Chemspace
CSSS00015191580
https://chem-space.com/CSSS00015191580
Debye Scientific
DB-072238
http://www.debyesci.com/cas_570406-98-3.html
Finetech
FT-0728753
http://www.finetechnology-ind.com/prod/detail/pub/570406-98-3.html
Lab Network
LN01341838
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01341838
Matrix Scientific
148389
https://www.matrixscientific.com/148389.html
MedChem Express
HY-13463
https://www.medchemexpress.com/avatrombopag.html
Molcore
MC561084
https://www.molcore.com/product/570406-98-3
Selleck Chemicals
S6624
http://www.selleckchem.com/products/avatrombopag.html
Smolecule
S519822
http://www.smolecule.com/products/s519822
Synblock Inc
SB16846
http://www.synblock.com/product/570406-98-3.html
THE BioTek
bt-261048
https://www.thebiotek.com/product/inhibitors/bt-261048
eNovation Chemicals
D672684
https://www.enovationchem.com/ProductDetails.asp?ProductID=D672684
eNovation Chemicals
Y1084033
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1084033
PubMed

PubMed

TitleDatePubMed
AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.
2008 Oct
AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.
2009 Apr
Romiplostim: a second-generation thrombopoietin agonist.
2009 Mar
Patents

Patents

20050153977
2

Sample Use Guides

In Vivo Use Guide
For patients with a platelet count 40000 to <50000/mm3: 40 mg once daily for 5 consecutive days, orally. For patients with platelet count below 40,000/mm3: 60 mg once daily for 5 consecutive days.
Route of Administration: Oral
In Vitro Use Guide
Avatrombopag stimulated the proliferation of cells expressing the human thrombopoietin receptor (c-Mpl) with an EC50 value of 3.3 nM and promoted the differentiation of human hematopoietic progenitor cells (cord blood CD34+ cells) to megakaryocytes with an EC50 value of 25.0 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:11 GMT 2023
Edited
by admin
on Fri Dec 15 16:35:11 GMT 2023
Record UNII
3H8GSZ4SQL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AVATROMBOPAG
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
YM-301477
Code English
avatrombopag [INN]
Common Name English
AKR-501
Common Name English
YM-477
Code English
AVATROMBOPAG [USAN]
Common Name English
Avatrombopag [WHO-DD]
Common Name English
E5501
Code English
E-5501
Code English
AVATROMBOPAG [MI]
Common Name English
1-(3-Chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylic acid
Systematic Name English
1-(3-CHLORO-5-((4-(4-CHLOROTHIOPHEN-2-YL)-5-(4-CYCLOHEXYLPIPERAZIN-1-YL)THIAZOL-2-YL)CARBAMOYL)-2-PYRIDYL)PIPERIDINE-4-CARBOXYLIC ACID
Systematic Name English
Classification Tree Code System Code
WHO-ATC B02BX08
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
NCI_THESAURUS C78275
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
Code System Code Type Description
MERCK INDEX
m12070
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
DRUG CENTRAL
5285
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
PUBCHEM
9852519
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
INN
9571
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
CAS
570406-98-3
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
EVMPD
SUB121659
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
NCI_THESAURUS
C150559
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
DAILYMED
3H8GSZ4SQL
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID30205667
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
WIKIPEDIA
Avatrombopag
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
RXCUI
2045726
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
FDA UNII
3H8GSZ4SQL
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
ChEMBL
CHEMBL2103883
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
USAN
YY-98
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
SMS_ID
100000144842
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
DRUG BANK
DB11995
Created by admin on Fri Dec 15 16:35:11 GMT 2023 , Edited by admin on Fri Dec 15 16:35:11 GMT 2023
PRIMARY
Related Record Type Details
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> INHIBITOR
IC50
Structure of AVATROMBOPAG
EXCRETED UNCHANGED
FECAL
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INDUCER
WEAK
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
THROMBOPOIETIN RECEPTOR
TARGET -> AGONIST
CYTOCHROME P450 2C8
METABOLIC ENZYME -> INDUCER
In vitro data suggests that avatrombopag weakly induces CYP2C8 and CYP2C9
WEAK
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
OAT-3
TRANSPORTER -> INHIBITOR
IC50
Structure of AVATROMBOPAG MALEATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 1-(5-((4-(4-CHLORO-2-THIENYL)-5-(4-CYCLOHEXYLPIPERAZIN-1-YL)THIAZOL-2-YL)CARBAMOYL)-3-HYDROXY-2-PYRIDYL)PIPERIDINE-4-CARBOXYLIC ACID
METABOLITE -> PARENT
Avatrombopag's metabolites were detected in feces. There were no metabolites detected in plasma.
Structure of 5-CHLORO-N-(4-(4-CHLORO-2-THIENYL)-5-(4-CYCLOHEXYL-1-PIPERAZINYL)-2-THIAZOLYL)-6-(4-HYDROXY-1-PIPERIDINYL)-3-PYRIDINECARBOXAMIDE
METABOLITE -> PARENT
Avatrombopag's metabolites were detected in feces. There were no metabolites detected in plasma.
MAJOR
Related Record Type Details
Structure of AVATROMBOPAG
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC
Blood-to-Plasma Ratio PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966